ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1482

Evaluation of T Cell Subpopulations, CD4/CD8 Ratio and p16INK4a in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Abstract Number: 1363

Evaluation of the Clinical Outcome of Baricitinib in Patients with Rheumatoid Arthritis from Multi-center Collaborative Study in Japan: Sub-analysis for Difficult-to-treat RA.
Abstract Number: 2296

Evaluation of the Dual Mode of Action of Ianalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren’s Disease: Results From a Phase 2 Mechanistic Study
Abstract Number: 1115

Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
Abstract Number: 2300

Evaluation of the Ianalumab Treatment Effects on Major Salivary Glands of Patients With Sjögren’s Disease by Multimodal Ultrasound: Results From a Phase 2 Mechanistic Study
Abstract Number: 2609

Evaluation of the Performance of Candidate Enthesitis Ultrasound Scoring Systems for Psoriatic Arthritis Diagnosis – DUET Study
Abstract Number: 1483

Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls
Abstract Number: 0652

Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
Abstract Number: 2520

Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort
Abstract Number: 1312

Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department
Abstract Number: 2412

Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis
Abstract Number: 2133

Examination of HLA-DRB1*15-linked Candidate Antigens in Still’s Disease with and without Lung Disease and Features of Drug Hypersensitivity
Abstract Number: 1871

Examining the impact of ETV2 on altered endothelial phenotype in systemic sclerosis
Abstract Number: 1410

Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Abstract Number: 1721

Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].